{"id":"NCT03632720","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","officialTitle":"Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-10-10","primaryCompletion":"2022-12-05","completion":"2022-12-05","firstPosted":"2018-08-15","resultsPosted":"2023-11-07","lastUpdate":"2023-11-07"},"enrollment":788,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Healthy Volunteers (Meningococcal Infection)"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine","otherNames":["MenACYW Conjugate vaccine"]},{"type":"BIOLOGICAL","name":"Meningococcal group B vaccine","otherNames":["Bexsero®"]},{"type":"BIOLOGICAL","name":"Diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis (inactivated) vaccine","otherNames":["Infanrix hexa®"]},{"type":"BIOLOGICAL","name":"Human rotavirus RIX4414 strain vaccine","otherNames":["Rotarix®"]},{"type":"BIOLOGICAL","name":"Pneumococcal 13-valent polysaccharide conjugate vaccine","otherNames":["Prevenar 13®"]}],"arms":[{"label":"Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)","type":"EXPERIMENTAL"},{"label":"Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)","type":"EXPERIMENTAL"},{"label":"Group 3: Bexsero® (2, 4, and 12 to 13 Months)","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of the study was to demonstrate the non-inferiority of the antibody responses to meningococcal serogroups A, C, W, and Y (MenACYW) in terms of serum bactericidal assay using human complement (hSBA) vaccine seroprotection (antibody titer greater than or equal to \\[\\>=\\] 1:8) when MenACYW Conjugate vaccine was administered concomitantly with Bexsero® in the second year of life compared to when MenACYW Conjugate vaccine was given alone.\n\nThe secondary objectives were to compare the hSBA antibody response in terms of geometric mean titers (GMTs) against meningococcal serogroups A, C, W, and Y when MenACYW Conjugate vaccine was administered concomitantly with Bexsero® or when MenACYW Conjugate vaccine was given alone in the second year of life; to describe the hSBA and serum bactericidal assay using baby rabbit complement (rSBA) antibody responses against meningococcal serogroups A, C, W, and Y before and after the 1st dose of MenACYW Conjugate vaccine administered at 3 months of age, before and after the 2nd dose of MenACYW Conjugate vaccine administered at 12 to 13 months of age for Group 1 and Group 2; to describe the hSBA and rSBA antibody persistence against meningococcal serogroups A, C, W, and Y after the 1st dose of MenACYW Conjugate vaccine administered at 3 months of age for Group 1 and Group 2.","primaryOutcome":{"measure":"Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 1:8 Against Meningococcal Serogroups A, C, Y, and W Measured by hSBA After Vaccination: Groups 1 and 2 - PPAS3","timeFrame":"30 days post-vaccination at the age of 12 to 13 months (i.e., at the age of 13 to 14 months)","effectByArm":[{"arm":"Group 1: MenACYW Conjugate Vaccine + Bexsero® (2, 4, and 12 to 13 Months)","deltaMin":100,"sd":null},{"arm":"Group 2: MenACYW Conjugate Vaccine + Bexsero® (2 and 4 Months)","deltaMin":99.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"56 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":19},"locations":{"siteCount":13,"countries":["United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":314},"commonTop":["Irritability","Injection Site Erythema","Crying","Somnolence","Injection Site Pain"]}}